YHB Investment Advisors Inc. Sells 1,533 Shares of Johnson & Johnson $JNJ

Key Points

• YHB Investment Advisors Inc. has reduced its stock position in Johnson & Johnson by 5.4%, now holding 26,957 shares worth approximately $4.12 million after selling 1,533 shares in the second quarter.
• Wall Street analysts have raised their price targets for Johnson & Johnson, with Citigroup and JPMorgan both increasing their targets to $200, while the stock maintains an average rating of "Moderate Buy."
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, yielding 3.0% annually, and reported a net profit margin of 25% for the last quarter.

YHB Investment Advisors Inc. cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,957 shares of the company's stock after selling 1,533 shares during the period. YHB Investment Advisors Inc.'s holdings in Johnson & Johnson were worth $4,118,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Brighton Jones LLC raised its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Hudson Value Partners LLC boosted its stake in shares of Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after purchasing an additional 1,022 shares in the last quarter. Two Sigma Investments LP acquired a new position in Johnson & Johnson during the 4th quarter worth about $9,222,000. First Heartland Consultants Inc. acquired a new position in Johnson & Johnson during the 4th quarter valued at about $1,269,000. Finally, 49 Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $211,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded up $1.81 on Friday, hitting $175.97. The company's stock had a trading volume of 25,617,065 shares, compared to its average volume of 6,995,150. The company has a market capitalization of $423.80 billion, a price-to-earnings ratio of 18.82, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The firm has a fifty day moving average price of $172.80 and a 200-day moving average price of $161.67. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's payout ratio is presently 55.61%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on JNJ shares. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. UBS Group boosted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Finally, Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $177.87.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.